Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Neuroinflammation in Patients With OCD
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 21
- Registration Number
- NCT04786548
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 44
- Registration Number
- NCT04765644
- Locations
- 🇬🇧
Imperial College Clinical Research Facility, London, United Kingdom
Adjunctive Celecoxib in Childhood-onset OCD Study
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 80
- Registration Number
- NCT04673578
- Locations
- 🇨🇦
BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada
Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- HK inno.N Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT04639804
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04526197
- Locations
- 🇺🇸
Clinical Trial Site, Austin, Texas, United States
Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography
- Conditions
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Aswan University Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04505657
- Locations
- 🇪🇬
Aswan University Hospital, Aswan, Egypt
Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs
- Conditions
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 110
- Registration Number
- NCT04490434
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT04469530
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia, United States
🇺🇸Texas Children's Cancer Center, Houston, Texas, United States
Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 68
- Registration Number
- NCT04429022
- Locations
- 🇺🇸
Millard Fillmore Suburban Hospital, Williamsville, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.